🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Myelofibrosis

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms NCT06034002Phase 113 sites📍 Duarte📍 Palo Alto📍 Miami Incyte Corporation · Tests: INCA033989, Ruxolitinib High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly NCT06345495Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam, Eltrombopag, Busulfan Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis NCT04370301Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Cyclophosphamide, JAK Inhibitor, Fludarabine, Recombinant Granulocyte Colony-Stimulating Factor, Melphalan Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia NCT07394153Phase 213 sites📍 Barcelona📍 Barcelona📍 Barcelona Grupo Español de Enfermedades Mieloproliferativas Crónicas … · Tests: Pacritinib A Telehealth Advance Care Planning Intervention NCT05875805NA1 site📍 Rochester University of Rochester · Tests: Telehealth Serious Illness Care Program, Education Control A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms NCT07849231Phase 136 sites📍 Birmingham📍 Gilbert📍 Duarte Damora Therapeutics · Tests: DMR-001, Ruxolitinib MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms NCT07863466n/a1 site📍 Milan Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant NCT06059391Phase 23 sites📍 Duarte📍 Atlanta📍 Boston City of Hope Medical Center · Tests: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hema… Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes NCT06361641NA3 sites📍 Angers📍 Cholet📍 Saumur University Hospital, Angers · Tests: Monocytes signatures in myeloproliferative neoplasms at diagnosis Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera NCT06516406n/a26 sites📍 Cosenza📍 Reggio Calabria📍 Naples IRCCS Azienda Ospedaliero-Universitaria di Bologna A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials NCT04064060Phase 3143 sites📍 Los Angeles📍 Oakland📍 Stanford Celgene · Tests: Luspatercept A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant NCT07020533Phase 13 sites📍 Duarte📍 Atlanta📍 Boston City of Hope Medical Center · Tests: Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation, Letermovir,… Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis NCT06770842Phase 21 site📍 Hong Kong The University of Hong Kong · Tests: Ropeginterferon alfa-2b (BESREMi®) Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined NCT06414681EARLY Phase 11 site📍 Fairway University of Kansas Medical Center · Tests: Tagraxofusp, Pacritinib Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects NCT07480824Phase 12 sites📍 Luoyang📍 Jinan Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TQ05105 Quantitative MRI for Myelofibrosis NCT01973881n/a1 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: T1 Weighted MRI (magnetic resonance imaging) A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) NCT06122831Phase 1, Phase 222 sites📍 Guangzhou📍 Nanning📍 Cangzhou Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TQ05105 Tablets, TQB3617 Capsules Therapeutic RSK1 Targeting in Myeloid Malignancies NCT07379125Phase 11 site📍 St Louis Washington University School of Medicine · Tests: PMD-026 Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia NCT05320198Phase 1, Phase 235 sites📍 Gilbert📍 Duarte📍 Irvine Disc Medicine, Inc · Tests: DISC-0974 Safety and Tolerability of ZE74-0282 in Healthy Volunteers NCT07527221Phase 11 site📍 Randwick Eilean Therapeutics AU Pty Ltd · Tests: ZE74-0282-0001 or placebo A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib NCT07623161Phase 3195 sites📍 Gilbert📍 Glendale📍 Whittier Takeda · Tests: Placebo, Elritercept A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis NCT07551427Phase 224 sites📍 Hefei📍 Fuzhou📍 Guangzhou Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TQ05105 Tablets (Rovadicitinib Tablets) A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation NCT06859424Phase 213 sites📍 Birmingham📍 Duarte📍 Palo Alto Center for International Blood and Marrow Transplant Resear… · Tests: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) NCT06351631Phase 321 sites📍 Ann Arbor📍 Durham📍 Columbus Merck Sharp & Dohme LLC · Tests: Bomedemstat A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) NCT07357727Phase 3148 sites📍 Denver📍 New Haven📍 Fort Myers Novartis Pharmaceuticals · Tests: Pelabresib, Ruxolitinib, Placebo An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms NCT05123365Phase 1, Phase 22 sites📍 Irvine📍 Orange University of California, Irvine · Tests: N-Acetylcysteine Mos-FED (Mosaicism in Focal Epilepsy Cortical Dysplasia Tissue) NCT06053671NA1 site📍 London King's College Hospital NHS Trust · Tests: Blood and nasal swab sampling Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis NCT07521046Phase 11 site📍 Salt Lake City University of Utah · Tests: ropeginterferon alfa- 2b, Ruxolitinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy